Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5621831 | Thrombosis Research | 2017 | 8 Pages |
Abstract
For patients with creatinine clearance between 50 and 95Â ml/min, apixaban 5Â mg was the most cost-effective treatment for willingness-to-pay thresholds (WTP) above $115,000/QALY gained, and edoxaban 60Â mg was cost-effective when the WTP was between $75,000 and $115,000/QALY gained. For patients with creatinine clearance >Â 95Â ml/min, apixaban 5Â mg was the most cost-effective treatment for WTP thresholds above $80,000/QALY gained.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Inmaculada PharmD, PhD, Kenneth J. MD, MS, Yuting PhD,